Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease

William P. Parker, Brian J. Davis, Sean S Park, Kenneth R. Olivier, Richard Choo, Mark A. Nathan, Val Lowe, Timothy J. Welch, Jaden D. Evans, William S. Harmsen, Harras B. Zaid, Ilya Sobol, Daniel M. Moriera, Rimki Haloi, Matthew K. Tollefson, Matthew T. Gettman, Stephen A. Boorjian, Lance A. Mynderse, Robert Jeffrey Karnes, Eugene D Kwon

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Management of recurrent prostate cancer (CaP) after radiotherapy (RT) is dependent on accurate localization of the site of recurrent disease. Objective: To describe the anatomic patterns and clinical features associated with CaP recurrence following RT identified on advanced imaging. Design, setting, and participants: Retrospective review of 184 patients with a rising prostate-specific antigen (PSA) after RT for CaP. Intervention: C-11 choline positron emission tomography/computed tomography (CholPET). Outcome measurements and statistical analysis: Recurrence patterns were classified as pelvic soft tissue only (as a surrogate for potentially salvageable disease) versus any extrapelvic disease, and clinical features were compared between patterns. Multivariable logistic regression was used to generate a predictive nomogram for extrapelvic recurrence. Discrimination was assessed with a . c-index. Results and limitations: Recurrence site was identified in 161 (87%) patients, with 95 (59%) sites histologically confirmed. Factors associated with the detection of recurrence included the difference between PSA nadir and PSA at CholPET (odds ratio: 1.30, . p . <. 0.01) and . National Comprehensive Cancer Network high-risk classification (odds ratio: 10.83, . p=0.03). One hundred (54.3%) patients recurred in the pelvic soft tissue only, while 61 (33%) had extrapelvic recurrence. Of 21 patients who underwent CholPET prior to meeting the Phoenix criteria of biochemical failure, 15 (71%) had recurrence identified on CholPET with 11 localized to the pelvis. On multivariable analysis, the difference between PSA nadir and PSA at CholPET, time from RT, and . National Comprehensive Cancer Network risk group were predictive of recurrence outside of the pelvis, and a nomogram was generated with a . c-index of 0.79. Conclusions: CholPET identified the site of recurrence in 87% of patients with a rising PSA after RT; most commonly within the pelvis in potentially salvageable locations. A predictive nomogram was generated, and pending external validation, this may aid in assessing the risk of disease beyond the pelvis. These findings underscore the importance of advanced imaging when considering management strategies for patients with a rising PSA following primary RT. Patient summary: We identified anatomic patterns of recurrence in patients with a rising prostate-specific antigen after radiotherapy using C-11 choline positron emission tomography/computed tomography. Most recurrences were localized to the pelvis and we were able to generate a tool to aid in disease localization prior to evaluation with advanced imaging. Using C-11 choline positron emission tomography/computed tomography we were able to identify the sites of recurrence in most patients presenting with a rising prostate-specific antigen following primary radiotherapy. Using these data we generated a predictive model for the identification of recurrence outside of the pelvis which, pending validation, may aid in the treatment of patients with a rising prostate-specific antigen following radiotherapy.

Original languageEnglish (US)
JournalEuropean Urology
DOIs
StateAccepted/In press - 2016

Fingerprint

Nomograms
Choline
Prostatic Neoplasms
Prostate-Specific Antigen
Radiotherapy
Recurrence
Pelvis
Positron Emission Tomography Computed Tomography
Odds Ratio
Neoplasms

Keywords

  • Nomogram
  • PET/CT
  • Prostate Cancer
  • Radiation Therapy
  • Recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography : A Nomogram for Predicting Extrapelvic Disease. / Parker, William P.; Davis, Brian J.; Park, Sean S; Olivier, Kenneth R.; Choo, Richard; Nathan, Mark A.; Lowe, Val; Welch, Timothy J.; Evans, Jaden D.; Harmsen, William S.; Zaid, Harras B.; Sobol, Ilya; Moriera, Daniel M.; Haloi, Rimki; Tollefson, Matthew K.; Gettman, Matthew T.; Boorjian, Stephen A.; Mynderse, Lance A.; Karnes, Robert Jeffrey; Kwon, Eugene D.

In: European Urology, 2016.

Research output: Contribution to journalArticle

Parker, William P. ; Davis, Brian J. ; Park, Sean S ; Olivier, Kenneth R. ; Choo, Richard ; Nathan, Mark A. ; Lowe, Val ; Welch, Timothy J. ; Evans, Jaden D. ; Harmsen, William S. ; Zaid, Harras B. ; Sobol, Ilya ; Moriera, Daniel M. ; Haloi, Rimki ; Tollefson, Matthew K. ; Gettman, Matthew T. ; Boorjian, Stephen A. ; Mynderse, Lance A. ; Karnes, Robert Jeffrey ; Kwon, Eugene D. / Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography : A Nomogram for Predicting Extrapelvic Disease. In: European Urology. 2016.
@article{4c33d22f10554f36b4fca27b23272f49,
title = "Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography: A Nomogram for Predicting Extrapelvic Disease",
abstract = "Background: Management of recurrent prostate cancer (CaP) after radiotherapy (RT) is dependent on accurate localization of the site of recurrent disease. Objective: To describe the anatomic patterns and clinical features associated with CaP recurrence following RT identified on advanced imaging. Design, setting, and participants: Retrospective review of 184 patients with a rising prostate-specific antigen (PSA) after RT for CaP. Intervention: C-11 choline positron emission tomography/computed tomography (CholPET). Outcome measurements and statistical analysis: Recurrence patterns were classified as pelvic soft tissue only (as a surrogate for potentially salvageable disease) versus any extrapelvic disease, and clinical features were compared between patterns. Multivariable logistic regression was used to generate a predictive nomogram for extrapelvic recurrence. Discrimination was assessed with a . c-index. Results and limitations: Recurrence site was identified in 161 (87{\%}) patients, with 95 (59{\%}) sites histologically confirmed. Factors associated with the detection of recurrence included the difference between PSA nadir and PSA at CholPET (odds ratio: 1.30, . p . <. 0.01) and . National Comprehensive Cancer Network high-risk classification (odds ratio: 10.83, . p=0.03). One hundred (54.3{\%}) patients recurred in the pelvic soft tissue only, while 61 (33{\%}) had extrapelvic recurrence. Of 21 patients who underwent CholPET prior to meeting the Phoenix criteria of biochemical failure, 15 (71{\%}) had recurrence identified on CholPET with 11 localized to the pelvis. On multivariable analysis, the difference between PSA nadir and PSA at CholPET, time from RT, and . National Comprehensive Cancer Network risk group were predictive of recurrence outside of the pelvis, and a nomogram was generated with a . c-index of 0.79. Conclusions: CholPET identified the site of recurrence in 87{\%} of patients with a rising PSA after RT; most commonly within the pelvis in potentially salvageable locations. A predictive nomogram was generated, and pending external validation, this may aid in assessing the risk of disease beyond the pelvis. These findings underscore the importance of advanced imaging when considering management strategies for patients with a rising PSA following primary RT. Patient summary: We identified anatomic patterns of recurrence in patients with a rising prostate-specific antigen after radiotherapy using C-11 choline positron emission tomography/computed tomography. Most recurrences were localized to the pelvis and we were able to generate a tool to aid in disease localization prior to evaluation with advanced imaging. Using C-11 choline positron emission tomography/computed tomography we were able to identify the sites of recurrence in most patients presenting with a rising prostate-specific antigen following primary radiotherapy. Using these data we generated a predictive model for the identification of recurrence outside of the pelvis which, pending validation, may aid in the treatment of patients with a rising prostate-specific antigen following radiotherapy.",
keywords = "Nomogram, PET/CT, Prostate Cancer, Radiation Therapy, Recurrence",
author = "Parker, {William P.} and Davis, {Brian J.} and Park, {Sean S} and Olivier, {Kenneth R.} and Richard Choo and Nathan, {Mark A.} and Val Lowe and Welch, {Timothy J.} and Evans, {Jaden D.} and Harmsen, {William S.} and Zaid, {Harras B.} and Ilya Sobol and Moriera, {Daniel M.} and Rimki Haloi and Tollefson, {Matthew K.} and Gettman, {Matthew T.} and Boorjian, {Stephen A.} and Mynderse, {Lance A.} and Karnes, {Robert Jeffrey} and Kwon, {Eugene D}",
year = "2016",
doi = "10.1016/j.eururo.2016.08.055",
language = "English (US)",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",

}

TY - JOUR

T1 - Identification of Site-specific Recurrence Following Primary Radiation Therapy for Prostate Cancer Using C-11 Choline Positron Emission Tomography/Computed Tomography

T2 - A Nomogram for Predicting Extrapelvic Disease

AU - Parker, William P.

AU - Davis, Brian J.

AU - Park, Sean S

AU - Olivier, Kenneth R.

AU - Choo, Richard

AU - Nathan, Mark A.

AU - Lowe, Val

AU - Welch, Timothy J.

AU - Evans, Jaden D.

AU - Harmsen, William S.

AU - Zaid, Harras B.

AU - Sobol, Ilya

AU - Moriera, Daniel M.

AU - Haloi, Rimki

AU - Tollefson, Matthew K.

AU - Gettman, Matthew T.

AU - Boorjian, Stephen A.

AU - Mynderse, Lance A.

AU - Karnes, Robert Jeffrey

AU - Kwon, Eugene D

PY - 2016

Y1 - 2016

N2 - Background: Management of recurrent prostate cancer (CaP) after radiotherapy (RT) is dependent on accurate localization of the site of recurrent disease. Objective: To describe the anatomic patterns and clinical features associated with CaP recurrence following RT identified on advanced imaging. Design, setting, and participants: Retrospective review of 184 patients with a rising prostate-specific antigen (PSA) after RT for CaP. Intervention: C-11 choline positron emission tomography/computed tomography (CholPET). Outcome measurements and statistical analysis: Recurrence patterns were classified as pelvic soft tissue only (as a surrogate for potentially salvageable disease) versus any extrapelvic disease, and clinical features were compared between patterns. Multivariable logistic regression was used to generate a predictive nomogram for extrapelvic recurrence. Discrimination was assessed with a . c-index. Results and limitations: Recurrence site was identified in 161 (87%) patients, with 95 (59%) sites histologically confirmed. Factors associated with the detection of recurrence included the difference between PSA nadir and PSA at CholPET (odds ratio: 1.30, . p . <. 0.01) and . National Comprehensive Cancer Network high-risk classification (odds ratio: 10.83, . p=0.03). One hundred (54.3%) patients recurred in the pelvic soft tissue only, while 61 (33%) had extrapelvic recurrence. Of 21 patients who underwent CholPET prior to meeting the Phoenix criteria of biochemical failure, 15 (71%) had recurrence identified on CholPET with 11 localized to the pelvis. On multivariable analysis, the difference between PSA nadir and PSA at CholPET, time from RT, and . National Comprehensive Cancer Network risk group were predictive of recurrence outside of the pelvis, and a nomogram was generated with a . c-index of 0.79. Conclusions: CholPET identified the site of recurrence in 87% of patients with a rising PSA after RT; most commonly within the pelvis in potentially salvageable locations. A predictive nomogram was generated, and pending external validation, this may aid in assessing the risk of disease beyond the pelvis. These findings underscore the importance of advanced imaging when considering management strategies for patients with a rising PSA following primary RT. Patient summary: We identified anatomic patterns of recurrence in patients with a rising prostate-specific antigen after radiotherapy using C-11 choline positron emission tomography/computed tomography. Most recurrences were localized to the pelvis and we were able to generate a tool to aid in disease localization prior to evaluation with advanced imaging. Using C-11 choline positron emission tomography/computed tomography we were able to identify the sites of recurrence in most patients presenting with a rising prostate-specific antigen following primary radiotherapy. Using these data we generated a predictive model for the identification of recurrence outside of the pelvis which, pending validation, may aid in the treatment of patients with a rising prostate-specific antigen following radiotherapy.

AB - Background: Management of recurrent prostate cancer (CaP) after radiotherapy (RT) is dependent on accurate localization of the site of recurrent disease. Objective: To describe the anatomic patterns and clinical features associated with CaP recurrence following RT identified on advanced imaging. Design, setting, and participants: Retrospective review of 184 patients with a rising prostate-specific antigen (PSA) after RT for CaP. Intervention: C-11 choline positron emission tomography/computed tomography (CholPET). Outcome measurements and statistical analysis: Recurrence patterns were classified as pelvic soft tissue only (as a surrogate for potentially salvageable disease) versus any extrapelvic disease, and clinical features were compared between patterns. Multivariable logistic regression was used to generate a predictive nomogram for extrapelvic recurrence. Discrimination was assessed with a . c-index. Results and limitations: Recurrence site was identified in 161 (87%) patients, with 95 (59%) sites histologically confirmed. Factors associated with the detection of recurrence included the difference between PSA nadir and PSA at CholPET (odds ratio: 1.30, . p . <. 0.01) and . National Comprehensive Cancer Network high-risk classification (odds ratio: 10.83, . p=0.03). One hundred (54.3%) patients recurred in the pelvic soft tissue only, while 61 (33%) had extrapelvic recurrence. Of 21 patients who underwent CholPET prior to meeting the Phoenix criteria of biochemical failure, 15 (71%) had recurrence identified on CholPET with 11 localized to the pelvis. On multivariable analysis, the difference between PSA nadir and PSA at CholPET, time from RT, and . National Comprehensive Cancer Network risk group were predictive of recurrence outside of the pelvis, and a nomogram was generated with a . c-index of 0.79. Conclusions: CholPET identified the site of recurrence in 87% of patients with a rising PSA after RT; most commonly within the pelvis in potentially salvageable locations. A predictive nomogram was generated, and pending external validation, this may aid in assessing the risk of disease beyond the pelvis. These findings underscore the importance of advanced imaging when considering management strategies for patients with a rising PSA following primary RT. Patient summary: We identified anatomic patterns of recurrence in patients with a rising prostate-specific antigen after radiotherapy using C-11 choline positron emission tomography/computed tomography. Most recurrences were localized to the pelvis and we were able to generate a tool to aid in disease localization prior to evaluation with advanced imaging. Using C-11 choline positron emission tomography/computed tomography we were able to identify the sites of recurrence in most patients presenting with a rising prostate-specific antigen following primary radiotherapy. Using these data we generated a predictive model for the identification of recurrence outside of the pelvis which, pending validation, may aid in the treatment of patients with a rising prostate-specific antigen following radiotherapy.

KW - Nomogram

KW - PET/CT

KW - Prostate Cancer

KW - Radiation Therapy

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84994891113&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994891113&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2016.08.055

DO - 10.1016/j.eururo.2016.08.055

M3 - Article

C2 - 27597240

AN - SCOPUS:84994891113

JO - European Urology

JF - European Urology

SN - 0302-2838

ER -